Biopharmaceutical Company Partners With Novavax: COVID-19 Vaccine Co-commercialization

The financial terms of the deal are robust, with Novavax receiving an upfront payment of $500 million from Sanofi.

In the fight against COVID-19 and influenza, Sanofi and Novavax Inc. have announced a landmark co-exclusive licensing agreement. This massive partnership marks a pivotal step forward in addressing ongoing public health needs by co-commercializing COVID-19 vaccines and developing innovative COVID-19-Influenza combination vaccines, which could redefine se…